Exicure (NASDAQ:XCUR – Get Free Report) is projected to post its resultson Thursday, November 12th. Analysts expect the company to announce earnings of ($18.60) per share and revenue of $1.64 million for the quarter.
Exicure (NASDAQ:XCUR – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($18.60) by $18.42.
Exicure Trading Down 3.5%
Shares of NASDAQ XCUR opened at $0.97 on Thursday. The firm’s 50-day simple moving average is $1.18 and its 200 day simple moving average is $2.67. Exicure has a 12-month low of $0.88 and a 12-month high of $9.48.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Exicure in a report on Tuesday, September 8th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has a consensus rating of “Sell”.
Read Our Latest Stock Analysis on XCUR
About Exicure
Exicure, Inc is a biotechnology company that historically focused on developing therapeutics based on spherical nucleic acid (SNA) technology. The company’s platform was designed to use three-dimensional arrangements of nucleic acids to target specific genetic and biological pathways, with potential applications in diseases that are difficult to address using conventional drug-delivery approaches.
Exicure’s development programs included candidates for genetic and neurological disorders, as well as dermatological and other conditions.
See Also
- Five stocks we like better than Exicure
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
